The U.S. consumer price index, or CPI, rose by 8.5% in March, its highest inflation reading since 1981. For Americans concerned about falling stock prices and soaring inflation, U.S. I bonds may be an increasingly attractive option. The U.S. Department of the Treasury recently announced that I bonds will pay a 9.62% interest rate through October 2022, their highest yield since…
Three rising stars you’ll wish you bought in 10 years. Key Points Poshmark is in the driver’s seat of a booming market for secondhand clothing. People will still buy pet supplies from Chewy during a market downturn. Lululemon Athletica is changing the way people shop for fitness clothing. Whether you’re a seasoned investor or just getting started, it’s never fun…
“Some of the market’s most rewarding opportunities can be found in small-cap stocks,” declares the author of today’s article – and with that, he proceeds to highlight three of the most popular small-cap stocks right now among Robinhood investors. For these three stocks – which include a veterinary health company with a medical device that could help it tap into…
Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product…
The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about…
Pfizer, BioNTech, Moderna, Johnson & Johnson, Novavax: Which COVID vaccine stock is the best pick for investors seeking strong growth? What about those looking for income? And how about value investors? The author of today’s article assesses which vaccine stock is best for which type of investor, depending on which factor is the most important to them. For more, CLICK…
With the daily average coronavirus cases being above 150,000 in the U.S., investors have been going back to the old playbook that worked so well last year. This could explain why the tech sector is still performing so well,” notes the author of today’s article before proceeding to highlight four tech stocks in particular to watch this week. For these…
The coronavirus pandemic is surging. The economy is in a precarious state. The outcome of the presidential election may well be contested. International tensions are rising. And the author of today’s article advises that “These risks are presenting a once-in-a-lifetime chance to turbocharge your investment gains.” How? By trading options, which he argues is easier than many investors think. For…
“These companies are all making important strides in next-gen solutions for COVID-19, cancer and other sectors. But remember, they’re small companies in a risky space, nibble on them and be patient,” advise the authors of today’s article in regards to the seven “A-rated” aggressive biotech stocks they highlight. For these seven biotech stocks – and whether they could be “Master…
The portfolio manager of one biotech-focused hedge fund recently invested a total of $60 million in three biotech stocks – and given his strong performance record and ability to beat the wider biotech sector with his picks, it may be worth taking a look at his selections. For the three biotech stocks in question, CLICK HERE.